Precancerous skin lesions can be treated with topical targeted therapies to significantly reduce their size and inhibit the growth of cutaneous squamous cell carcinoma, the second most common form of cancer.
Two treatments—small-molecule kinase inhibitors known as dasatinib and BEZ-235—were associated with fewer side effects compared to 5-fluorouracil, the first-line topical agent that destroys precancerous and cancer cells, but is known to have adverse side effects.
Lesions known as actinic keratoses and squamous cell carcinoma in situ are known precursors to cutaneous squamous cell carcinoma. Every year, 700,000 new ones are reported to dermatologists in the United States, which incur treatment costs of about $1.6 billion. Today, many of the topical drugs used to treat them include 5-fluorouracil, imiquimod, diclofenac, and ingenol mebutate, but these agents have limitations. Some cause inflammation, have suboptimal results, or are very costly.
SOURCES- University of Pennsylvania
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.